UP!

BSX $37.12   View long term graphs

Boston Scientific
Type
Public
Traded as NYSE: BSX
S&P 500 Component
Industry Medical device
Founded 1979
Founders John Abele, Founder & Director Emeritus
Peter Nicholas, Founder & Director Emeritus
Headquarters Marlborough, Massachusetts, United States
Key people
Michael Mahoney, President, Chairman and CEO
Daniel Brennan, CFO
Revenue Increase $ 8.386 billion (2016)
Operating income
Increase $ (447 million) (2016)}}
Net income
Increase $ (142 million) (2016)}}
Number of employees
27,000 (December 2016)}}
Website www.bostonscientific.com

Boston Scientific Corporation (Boston Scientific) is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Boston Scientific is primarily known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (ICD) which they call the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD).


Boston Scientific was formed June 29, 1979 as a holding company for a medical products company called Medi-Tech, and to position the company for growth in interventional medicine.

The company went public through an IPO on May 19, 1992.

The Taxus Stent was approved in 2003 in Europe and other countries and approved in the United States by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.

On April 21, 2006, the company acquired longtime competitor Guidant for $27.2 billion. The former Guidant was split between BSC and Abbott Laboratories.

Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.

In October 2010, the company was fined $600,000 by the US Department of Justice for paying a US Army doctor to use their devices and recommend them to others.

In June 2012, Boston Scientific officially acquired Cameron Health for a total sum of $1.3 billion, paid out incrementally as various revenue milestones were achieved.

In March 2015, the company announced it would acquire Endo International Plc's urology business for at least $1.6 billion, expanding the company's health and prostate treatments.

Beginning in 2003, Boston Scientific and Johnson & Johnson were involved in a series of litigations involving patents covering heart stent medical devices. Both parties claimed that the other had infringed upon their patents. The litigation was settled once Boston Scientific agreed to pay $716 million to Johnson & Johnson in September 2009 and an additional $1.73 billion in February 2010.

It was announced in November 2014 that Johnson & Johnson would have another chance for payback after a multibillion dollar trial was set for 20 November 2014. A New York federal court judge would hear the case without a jury to decide whether Boston Scientific should be held liable for the contract breach.

On Nov 3,1998, Boston Scientific restated its financial results for 1997, as well as its quarterly results for the first three quarters of 1998, due to the occurrence of business irregularities in the operations of its Japanese subsidiary.

Profits rose to €887 million in 2015 in the Irish-based plant. In 2014 the profits were €766.65 million. Profits increased by 13.57% in one year.

Coordinates: 42°21′37.3″N 71°33′32.6″W / 42.360361°N 71.559056°W / 42.360361; -71.559056

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-03 Future report Set alerts
Q3 2020 2020-10-21 Future report Set alerts
Q2 2020 2020-07-29 0.08 -0.11
Q1 2020 2020-04-29 0.28 0.01
Q4 2019 2020-02-05 0.46 2.83
Q3 2019 2019-10-23 0.39 0.09
Q2 2019 2019-07-24 0.39 0.11
Q1 2019 2019-04-24 0.35 0.30
Q4 2018 2019-02-06 0.39 0.27
Q3 2018 2018-10-24 0.35 0.31

Ratings

2016-06-21 Reiterated Rating Piper Jaffray Overweight $26.00
2016-06-21 Reiterated Rating Piper Jaffray Cos. Overweight $26.00
2016-06-17 Reiterated Rating Leerink Swann Buy $25.50 to $27.50
2016-06-08 Initiated Coverage Guggenheim Buy $26.00
2016-05-25 Reiterated Rating Piper Jaffray Overweight $26.00
2016-05-23 Downgrade BTIG Research Buy to Neutral $24.20
2016-05-12 Reiterated Rating RBC Capital Outperform $25.00
2016-05-12 Reiterated Rating Royal Bank Of Canada Outperform $25.00
2016-04-28 Boost Price Target Wedbush Neutral $19.00 to $23.00
2016-04-28 Boost Price Target Stifel Nicolaus Buy $22.00 to $25.00
2016-04-28 Boost Price Target RBC Capital Outperform $22.00 to $25.00
2016-04-28 Boost Price Target Barclays Overweight $23.00 to $25.00
2016-04-28 Boost Price Target Barclays PLC Overweight $23.00 to $25.00
2016-04-27 Boost Price Target Needham & Company LLC Buy $22.00 to $26.00
2016-04-27 Boost Price Target Evercore ISI Buy $21.50 to $23.50
2016-04-27 Reiterated Rating Benchmark Co. Buy $20.00 to $22.00
2016-04-12 Boost Price Target RBC Capital Outperform $20.00 to $22.00
2016-04-10 Reiterated Rating Argus Hold
2016-04-08 Boost Price Target Goldman Sachs $21.00 to $22.00
2016-04-08 Boost Price Target Goldman Sachs Group Inc. $21.00 to $22.00
2016-04-06 Reiterated Rating Stifel Nicolaus Buy $22.00
2016-03-27 Reiterated Rating Morgan Stanley Overweight $22.00
2016-03-25 Reiterated Rating Bank of America Buy $23.00
2016-03-25 Reiterated Rating Bank of America Corp. Buy $23.00
2016-03-18 Initiated Coverage Longbow Research Buy
2016-03-17 Initiated Coverage Nomura Buy $22.00
2016-03-17 Initiated Coverage Nomura Holdings Inc. Buy $22.00
2016-03-12 Reiterated Rating Deutsche Bank Hold
2016-03-12 Reiterated Rating Deutsche Bank AG Hold
2016-02-25 Initiated Coverage SunTrust Buy $21.00
2016-02-25 Initiated Coverage SunTrust Banks Inc. Buy $21.00
2016-02-09 Reiterated Rating Stifel Nicolaus Buy
2016-02-07 Reiterated Rating Needham & Company LLC Buy $22.00
2016-02-07 Reiterated Rating BTIG Research Buy $20.00
2016-02-05 Reiterated Rating Leerink Swann Buy
2016-01-04 Boost Price Target Sterne Agee CRT Buy $21.00 to $22.50
2015-11-13 Reiterated Rating Evercore ISI Buy $20.00
2015-11-12 Reiterated Rating Needham & Company LLC Buy $22.00
2015-11-12 Reiterated Rating BTIG Research Buy $20.00
2015-11-12 Initiated Coverage Citigroup Inc. Buy $23.00
2015-11-11 Reiterated Rating Piper Jaffray Buy
2015-11-11 Reiterated Rating Leerink Swann Hold $21.00
2015-11-11 Reiterated Rating Deutsche Bank Hold $19.00
2015-10-29 Boost Price Target Wedbush Neutral $17.00 to $19.00
2015-10-29 Reiterated Rating Barclays Overweight $21.00 to $23.00
2015-10-28 Boost Price Target Needham & Company LLC Buy $21.00 to $22.00
2015-10-15 Reiterated Rating BTIG Research Buy $20.00
2015-10-06 Reiterated Rating Piper Jaffray Buy $21.00 to $22.50
2015-09-28 Upgrade Needham & Company LLC Hold to Buy $21.00
2015-09-06 Reiterated Rating BTIG Research Buy
2015-08-27 Upgrade Goldman Sachs Neutral to Buy $18.00 to $20.00
2015-08-10 Reiterated Rating Credit Suisse Buy
2015-08-10 Reiterated Rating Credit Suisse Group AG Buy
2015-07-26 Reiterated Rating BTIG Research Buy $20.00
2015-07-24 Boost Price Target Stifel Nicolaus Buy $19.00 to $20.00
2015-07-23 Boost Price Target Benchmark Co. Buy $19.00 to $20.00
2015-07-07 Initiated Coverage Stephens Overweight $21.00
2015-05-26 Initiated Coverage Evercore ISI Buy $20.50
2015-05-05 Reiterated Rating BTIG Research Buy $20.00
2015-05-04 Boost Price Target Deutsche Bank Hold $17.00 to $19.00
2015-04-29 Boost Price Target Barclays Overweight $20.00 to $21.00
2015-04-29 Reiterated Rating Needham & Company LLC Hold
2015-04-29 Boost Price Target Leerink Swann Outperform to Buy $18.00 to $21.00
2015-04-20 Boost Price Target RBC Capital Outperform $17.00 to $20.00
2015-03-30 Reiterated Rating Argus Hold
2015-03-23 Boost Price Target Barclays Overweight $19.00 to $20.00
2015-03-20 Initiated Coverage Raymond James Outperform $21.00
2015-03-20 Initiated Coverage Raymond James Financial Inc. Outperform $21.00
2015-03-19 Reiterated Rating Deutsche Bank Hold $17.00
2015-03-19 Reiterated Rating BTIG Research Buy $19.00
2015-03-18 Set Price Target Morgan Stanley Buy $20.00
2015-03-16 Boost Price Target BMO Capital Markets Outperform $18.00 to $19.00
2015-03-16 Boost Price Target Credit Suisse Outperform $18.00 to $19.00
2015-03-03 Boost Price Target Oppenheimer Market Perform $16.00 to $17.00
2015-03-03 Boost Price Target Oppenheimer Holdings Inc. Market Perform $16.00 to $17.00
2015-03-02 Set Price Target BTIG Research Buy $18.00
2015-02-26 Boost Price Target Deutsche Bank Hold $16.00 to $17.00
2015-02-18 Reiterated Rating Stifel Nicolaus Buy $17.00 to $18.00
2015-02-18 Boost Price Target JPMorgan Chase & Co. Overweight $17.50 to $18.00
2015-02-18 Boost Price Target Oppenheimer Outperform $15.00 to $16.00
2015-02-05 Boost Price Target JMP Securities Market Outperform $15.00 to $17.00
2015-02-05 Boost Price Target Deutsche Bank Hold $14.50 to $16.00
2015-02-05 Boost Price Target CRT Capital Buy $16.00 to $18.00
2015-02-05 Reiterated Rating Wedbush Neutral $17.00
2015-02-05 Boost Price Target Stifel Nicolaus Buy $16.00 to $17.00
2015-02-04 Reiterated Rating Bank of America Buy
2015-01-30 Upgrade BMO Capital Markets Market Perform to Outperform $15.00 to $18.00
2015-01-08 Upgrade Leerink Swann Market Perform to Outperform $15.00 to $18.00
2015-01-05 Upgrade JPMorgan Chase & Co. Neutral to Overweight
2014-10-23 Upgrade Goldman Sachs Sell to Neutral $11.00 to $13.00
2014-10-22 Upgrade Benchmark Co. Hold to Buy
2014-09-30 Initiated Coverage Needham & Company LLC Hold
2014-08-07 Reiterated Rating JPMorgan Chase & Co. Neutral $16.00 to $14.50
2014-07-29 Initiated Coverage Sterne Agee CRT Neutral $13.50
2014-07-25 Reiterated Rating JPMorgan Chase & Co. Neutral $14.00 to $16.00
2014-07-25 Reiterated Rating Barclays Overweight $14.00 to $15.00
2014-07-07 Initiated Coverage CRT Capital Buy to Buy $16.00
2014-06-10 Initiated Coverage Morgan Stanley Overweight $15.00
2014-04-30 Reiterated Rating Citigroup Inc. Hold $13.80
2014-04-23 Reiterated RBC Capital Mkts Outperform $14 to $15
2014-04-23 Boost Price Target RBC Capital Outperform $14.00 to $15.00
2014-04-21 Upgrade Ned Davis Research Sell to Neutral
2014-04-14 Boost Price Target Bank of America Neutral to Buy $7.00 to $9.00
2014-03-24 Upgrade Sanford C. Bernstein Market Perform to Outperform $12.00 to $15.00
2014-02-05 Boost Price Target Jefferies Group $12.00 to $13.00
2014-01-31 Boost Price Target Cowen and Company $14.00 to $15.00
2014-01-21 Upgrade Piper Jaffray Neutral to Overweight $12.00 to $18.00
2014-01-09 Boost Price Target Barclays Overweight $13.00 to $14.00
2014-01-07 Initiated Coverage BTIG Research Buy
2014-01-06 Upgrade Oppenheimer Equal Weight to Overweight $15.00
2014-01-06 Upgrade Morgan Stanley Equal Weight to Overweight $15.00
2013-12-06 Upgrade Cowen and Company Market Perform to Outperform
2013-12-05 Initiated The Benchmark Company Hold $12
2013-12-05 Initiated Coverage Benchmark Co. Hold $12.00
2013-11-22 Boost Price Target BMO Capital Markets $11.00 to $12.00
2013-10-28 Reiterated Deutsche Bank Hold $11 to $13
2013-10-25 Boost Price Target Deutsche Bank Hold $11.00 to $13.00
2013-10-25 Boost Price Target BMO Capital Markets Market Perform $10.00 to $11.00
2013-10-25 Boost Price Target Barclays Overweight $12.00 to $13.00
2013-10-25 Boost Price Target Jefferies Group Hold $10.00 to $12.00
2013-07-26 Reiterated Stifel Buy $11 to $13
2013-07-26 Reiterated RBC Capital Mkts Outperform $11 to $12
2013-07-26 Reiterated Barclays Overweight $9 to $12
2013-05-31 Reiterated RBC Capital Mkts Outperform $8 to $11
2013-05-16 Reiterated Stifel Buy $9 to $11
2013-05-08 Reiterated Barclays Overweight $8 to $9
2013-04-12 Reiterated Deutsche Bank Hold $7.20 to $7.90
2013-02-13 Reiterated Stifel Nicolaus Buy $8 to $9
2013-02-13 Reiterated Deutsche Bank Hold $6.70 to $7.20
2013-01-30 Reiterated Mizuho Neutral $5.10 to $6.80
2013-01-30 Reiterated Barclays Overweight $7 to $8
2013-01-04 Reiterated Deutsche Bank Hold $6.50 to $6.70
2012-11-20 Initiated Stifel Nicolaus Buy $6.50
2012-07-27 Reiterated Mizuho Neutral $5.90 to $5
2012-07-27 Downgrade Northland Securities Outperform to Market Perform $7.50 to $5.50
2012-03-02 Initiated Northland Securities Outperform $7.50
2016-06-21 Reiterated Rating Piper Jaffray Overweight $26.00
2016-06-21 Reiterated Rating Piper Jaffray Cos. Overweight $26.00
2016-06-17 Reiterated Rating Leerink Swann Buy $25.50 to $27.50
2016-06-08 Initiated Coverage Guggenheim Buy $26.00
2016-05-25 Reiterated Rating Piper Jaffray Overweight $26.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
NICHOLAS PETER M 0.26%  (3486965) BSX /
Mahoney Michael F President & CEO 0.16%  (2139770) BAX / BSX /
ABELE JOHN E Director Emeritus 0.04%  (500000) BSX /
Bose Supratim EVP & President, Asia-Pacific 0.02%  (320301) BSX / CFN /
Brennan Daniel J. EVP and CFO 0.02%  (279183) BSX /
Nanavaty Maulik SVP & Pres, Neuromodulation 0.02%  (232363) BSX /
Fitzgerald Joseph Michael SVP & President, CRM 0.01%  (186763) BSX /
REINHARDT UWE E 0.01%  (159379) BSX / HQH / HQL /
Pratt Timothy A. EVP, GC & Chief Admin Officer 0.01%  (154681) BSX /
Carruthers Wendy SVP, Human Resources 0.01%  (144468) BSX /
Phalen Michael P. EVP & President, MedSurg 0.01%  (133373) BSX /
Thepaut Eric Francis Yves SVP & Pres, Europe 0.01%  (132873) BSX /
Pucel Kenneth EVP, Glob Ops, Qual & Tech 0.01%  (128517) BSX / LNTH / PII /
Lance Jean Fitterer SVP & Chief Compliance Officer 0.01%  (117174) BSX /
Onuscheck John Michael SVP & President, Europe 0.01%  (116025) BSX /
BYRNES BRUCE L 0.01%  (112097) BSX / CBB / DBD /
Mirviss Jeffrey B. SVP&Pres, Periph Intervent 0.01%  (108485) BSX /
Wang Xin Warren SVP and Pres, Asia Pacific 0.01%  (101174) BSX /
MARIO ERNEST 0.01%  (86032) BSX / CAPN / CELG / CMRX / KIN / TNXP / VVUS / XNPT /
Mackey Edward F EVP, Operations 0.01%  (72752) BSX /
Ballinger Kevin J. SVP & Pres, Interven Cardio 0.01%  (71151) BSX /
Dawkins Keith D EVP, Global Chief Med. Off. 0.01%  (68165) BSX /

Comments